1	Streamlining Atrial Fibrillation Ablation Management Using a Digitization Solution
2	
3	Short title: A Digitization Ablation Solution Pilot Evaluation.
4	
5	Jim O'Brien <sup>1</sup> , Sergio Valsecchi <sup>2</sup> , PhD, Fionnuala Seaver <sup>1</sup> , Lorena Rosalejos <sup>1</sup> , Diana Arellano <sup>1</sup> ,
6	Kristine Laurilla <sup>1</sup> , Gael Jauvert <sup>1</sup> , Noel Fitzpatrick <sup>1</sup> , Tamas Tahin <sup>1,3</sup> , Ted Keelan <sup>1,4</sup> , Joe Galvin <sup>1,4,5</sup> ,
7	Gabor Szeplaki <sup>1,6</sup> , PhD
8	Author affiliations
9 10 11 12 13 14 15	<ul> <li><sup>1</sup>Atrial Fibrillation Institute, Mater Private Hospital, Dublin, Ireland</li> <li><sup>2</sup>Boston Scientific Inc., Natick, MA, USA</li> <li><sup>3</sup>Department of Cardiology, Zala Varmegyei Szent Rafael Hospital, Zalaegerszeg, Hungary</li> <li><sup>4</sup>Department of Cardiology, Mater Misericordiae University Hospital, Dublin, Ireland</li> <li><sup>5</sup>Health Sciences Centre, UCD School of Medicine, University College Dublin, Dublin, Ireland</li> <li><sup>6</sup>Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland</li> </ul>
16	Total word count: 6372
17	Corresponding author
18	Prof Gabor Szeplaki, MD, PhD
19	Head of Cardiac Electrophysiolgy
20	Mater Private Hospital, 73 Eccles Street, Dublin 7, D07 KWR1, Ireland
21	Email: szeplaki.gabor@gmail.com
22	Tel : +35318858279
23	Funding
24	The study was funded and medical writing service was provided by Boston Scientific Inc., (Natick,
25	MA, USA).
26	
27	Data availability statement
28	The data that support the findings of this study are available on request from the corresponding
29	author.
30	
31	
32	© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

#### **1** Conflict of interest

NF reports institutional educational support from Biosense Webster and Synapse Medical as well
as speakers fees from Daiichi Sankyo, unrelated to the submitted work. GS reports personal fees
from Abbott, Bayer, Boston Scientific, Bayer, Johnson and Johnson Medical and Luma Vision, not
related to the present study and consulting fees from Boston Scientific related to the present study.
The remaining authors declare that the research was conducted in the absence of any commercial
or financial relationships that could be construed as a potential conflict of interest.

# 8 ABSTRACT

9 Background: Catheter ablation is a widely accepted intervention for atrial fibrillation (AF)
10 management. Prior to undertaking this procedure, thorough patient education on its efficacy and

11 potential complications is crucial. Additionally, educating patients about stroke risk management

12 and anticoagulant therapy is imperative.

13 **Purpose:** At Mater Private Hospital in Dublin, we implemented a solution, integrating a

14 customized treatment pathway and a mobile application. This patient-centered approach aims to

15 optimize the clinical management of AF catheter ablation candidates, focusing on knowledge gaps

16 and adherence to guideline-based care to enhance overall outcomes.

17 Methods: The application automates pre-operative assessments and post-operative support,

18 facilitating seamless patient-clinician communication. During the observation period (September

19 2022 to April 2023), 63 patients installed the app.

20 **Results:** Patient adherence to the pathway was strong, with 98% of patients actively engaging in

21 the treatment pathway and with 81% completing all pre-operative tasks. The average enrollment-

- to-admission duration was 14 days, and post-ablation tasks were fulfilled by 62% of patients
- 23 within an average of 36 days. Operators perceived the solution as user-friendly and effective in
- 24 enhancing patient connectivity. Patient satisfaction was high, and knowledge about AF improved

1 notably through the solution, particularly concerning the recognition of symptoms and

2 anticoagulation therapy-related complications.

3 **Conclusions:** Our findings demonstrates the successful implementation of the app-based Ablation

4 Solution, showcasing widespread patient use, improved adherence, and enhanced understanding of

- 5 AF and its treatments. The system effectively connects healthcare providers with patients, offering
- 6 a promising approach to streamline AF catheter ablation management and improve patient

7 outcomes.

8 **KEYWORDS:** Atrial fibrillation; Catheter ablation; Outpatient care; Patient education;

9 Knowledge; patient engagement; care digitalization

10

### 11 INTRODUCTION

Atrial fibrillation (AF) stands as a prevalent cardiac rhythm disorder. Presently, it is estimated to 12 affect approximately 2% to 4% of adults, with an anticipated 2.3-fold increase attributed to 13 14 extended life expectancy in the general population and intensified efforts to detect undiagnosed AF (1). The complexity of AF necessitates a comprehensive and multidisciplinary approach to patient 15 16 management, with active patient involvement in collaboration with healthcare professionals. 17 Existing guidelines underscore the significance of a coordinated, patient-tailored care pathway to 18 deliver optimized treatment for AF patients (1). Patient awareness regarding AF and its 19 management often remains limited, especially at the time of initial diagnosis when many treatment 20 decisions are deliberated and made (2-6). It is imperative to ensure that patients receive 21 appropriate information on treatment choices, adherence guidelines, potential consequences of 22 non-adherence, and the realistic expectations of treatment outcomes to promote adherence 23 effectively.

1	Catheter ablation of AF is a well-established intervention for preventing AF recurrences (1). While
2	catheter ablation offers a safe and superior alternative to antiarrhythmic drugs for maintaining
3	sinus rhythm and alleviating symptoms, it is advisable to discuss its efficacy and potential
4	complications with patients before proposing the procedure. Furthermore, patients should be
5	thoroughly informed about the clinical signs and symptoms of rare but potentially serious ablation-
6	related complications that may manifest after hospital discharge. Additionally, patients should be
7	educated on the management of stroke risk and the use of oral anticoagulant therapy, both before
8	and after the ablation procedure.
9	In the Mater Private Hospital in Dublin, we have contributed to the development of a solution that
10	encompasses a customized treatment pathway, the ADVANTICS <sup>™</sup> Ablation Solution (Boston
11	Scientific Inc., Natick, MA, USA), which incorporates a patient mobile application. This
12	innovative approach is aimed at optimizing clinical practice in the management of patients
13	undergoing AF catheter ablation. The project focuses on creating a patient-centered, integrated
14	care strategy designed to streamline the care of AF catheter ablation candidates and bridge specific
15	knowledge gaps among patients. The ultimate goal is to facilitate the implementation of guideline-
16	based AF management and enhance patient outcomes.
17	This report seeks to provide an overview of the initial experiences with the implementation of the
18	ADVANTICS <sup>TM</sup> Ablation Solution in clinical practice.

19 METHODS

20 Solution description

The solution introduces changes to the traditional surgical pathway by standardizing, optimizing and automating labor-intensive, paper-based procedures. Its primary goal is to support hospitals in improving waiting list management, streamlining operations, and enhancing the overall experience 1 for healthcare providers and patients. The solution includes an advisory program to support the

2 digitization and a digital care coordination platform.

#### 3 Advisory program on patient engagement digitization

Following initial interviews with all healthcare professionals involved in AF treatment at the 4 center, the patient journey at Mater Private was mapped, focusing on the communication steps and 5 6 educational materials used. Based on the assessment, the pathway was then optimized and dedicated patient engagement materials were developed to be leveraged in the digital care path. 7 8 The platform underwent adaptation to align with the specific requirements and the optimized pathway related to the pre- and post-operative management of patients undergoing AF catheter 9 ablation. This involved establishing a clear sequence of events within the process, defining the 10 content of questionnaires, designating responsibility for data entry (whether by the clinical team or 11 patients), determining the timing of action execution, specifying patient notifications, and shaping 12 13 the educational material provided to patients regarding the disease and treatment (Figure 1). It was 14 therefore established that the presentation of the digital care path and the mobile application to the patient would be conducted by the administrative staff during the pre-procedural consultation visit. 15 Nurses would be responsible for clinical assessment, providing medication instructions via the 16 17 application, and postoperative instructions. The clinical and feedback questionnaires would be 18 completed by patients independently via the application, prompted by specific automatic 19 reminders. The information material included information about the disease, consequences of AF, 20 treatment options, role of anticoagulation, description of catheter ablation procedure (with risks), 21 importance of lifestyle and risk factor modification. Upon the completion of the system setup, the 22 staff received training on how to effectively utilize the web-based dashboard and patient materials 23 were produced and distributed to facilitate the adoption of the application.

#### 1 The digital platform

2 The digital care coordination platform (Buddy Healthcare, Helsinki, Finland) comprises a user-3 friendly application for patients and a web-based dashboard for clinicians. The patient application 4 offers the capability for patients to complete electronic forms, submit data from remote care devices, and engage in seamless communication with their clinical teams (Supplemental Figure 5 1). On the other hand, the clinician dashboard equips healthcare professionals with tools to enter 6 data (Supplemental Table 1) and review patient information, respond to alerts, and foster efficient 7 communication with patients (Supplemental Figure 2). This platform digitalizes the pre-operative 8 assessment process and facilitates digital post-operative support, encompassing the automated 9 collection and visualization of patient-reported experience and outcome measures. The system's 10 primary objective is to maintain effective communication between hospitals and patients who are 11 awaiting appointments and surgeries. It offers the functionality to confirm a patient's readiness for 12 13 surgery, reduce the necessity for traditional outpatient visits and phone calls, enhance patient education and engagement, and streamline data capture. 14

15 *Evaluation design* 

Throughout the pilot the usage by patients and clinical team was closely monitored to ensure 16 17 clinical team and patient satisfaction. The pilot evaluation of this solution commenced in 18 September 2022. Every patient referred to the center for de-novo AF ablation underwent a pre-19 procedural consultation to assess the suitability of AF treatment. After verification of the 20 availability of a mobile device by the patient or a caregiver, eligible patients for ablation were 21 informed about the project. The ones who were interested were enrolled and invited to download 22 the application, subsequently following the provided guidance. In April 2023, the operators were 23 requested to complete a specialized questionnaire, evaluating their experience with the Ablation

1	Solution. Patient feedback on	their experience	with the application v	was collected following their
---	-------------------------------	------------------	------------------------	-------------------------------

2 hospital discharge. The compliance of patients with the treatment pathway steps and their

3 adherence to specified execution timings were closely monitored. Additionally, patients were

4 given a dedicated questionnaire to assess their baseline knowledge of AF at the time of enrollment,

- 5 with a follow-up assessment conducted after hospital discharge (Supplemental Table 2).
- 6 For the purpose of this analysis, all data were de-identified in compliance with European
- 7 regulations (European General Data Protection Regulation UE 2016/679) to safeguard personal
- 8 health information. The data protection officer confirmed adherence to the relevant regulations.

9 Since this project involved a retrospective analysis of prospectively collected clinical data in real-

world settings, it was exempt from review and approval by the institutional review board. Patients
had granted written approval to contribute data at the time of inclusion.

12 Statistical analysis

Descriptive statistics are reported as means  $\pm$  standard deviation for normally distributed 13 14 continuous variables, or medians with ranges in the case of skewed distribution. Categorical data were expressed as percentages. Differences between mean data were compared by a t-test for 15 Gaussian variables. Differences in proportions were compared by a Chi-square analysis. A P value 16 17 <0.05 was considered significant for all tests. The results of the evaluation of the knowledge of AF 18 conducted at the time of enrollment and after hospital discharge were compared by assessing the 19 difference in the proportion of patients who answered the question correctly for single-choice 20 questions and the patient-based average of correct answers for multiple-choice questions. All 21 statistical analyses were performed by means of R: a language and environment for statistical 22 computing (R Foundation for Statistical Computing, Vienna, Austria).

#### 1 **RESULTS**

2 During the period spanning from September 2022 to April 2023, a total of 63 consecutive patients 3 successfully installed the mobile application. All invited patients installed the application. The 4 baseline characteristics of the population are detailed in **Table 1**. Four patients did not undergo the 5 ablation procedure (3 patients withdrew consent, and one found out she was pregnant). The remaining 59 patients underwent successful AF ablation, with the procedure involving the 6 isolation of pulmonary veins using a point-by-point radiofrequency ablation catheter technique 7 (12) or pulsed field ablation with irreversible electroporation (47). No complications were reported 8 during the procedures, and the postoperative period transpired without any noteworthy events for 9 all patients. The adherence of patients to the prescribed steps within the treatment pathway, as well 10 as their compliance with the specified execution timings, is depicted in Figure 2. Sixty-two (98%) 11 patients actively engaged in at least one task within the pathway, with a 81% of these individuals 12 successfully completing all the tasks designated for the pre-operative phase. The average duration 13 14 from enrollment to hospital admission was recorded at 14 days. Following the ablation procedure, the post-ablation pathway encompassed an average period of 36 days, and 62% of patients fulfilled 15 16 all the requisite tasks. Overall, the planned actions were largely executed within the expected 17 timelines. Survey responses regarding operator experiences with the Ablation Solution are reported 18 in **Table 2**. The majority of operators (cardiac electrophysiologists and arrhythmia nurse 19 specialists) found the system to be an effective tool for enhancing patient connectivity and optimizing the patient flow. However, they perceived fewer advantages in terms of reducing 20 21 follow-up time and streamlining information collection. Overall, the platform was judged easy to 22 use, complete and met operators' expectations. Additionally, operators recommended 23 implementing additional features to enhance the application. In terms of patient information

1	materials, they suggested the inclusion of descriptive procedure videos alongside a section
2	addressing frequently asked questions. Furthermore, they expressed a preference for remote
3	consent collection and patient self-registration to streamline the enrollment process and improve
4	efficiency. Survey responses gauging patient experiences with the mobile application are
5	documented in <b>Table 3</b> . The level of patient satisfaction was consistently high, with the
6	application being appraised for its user-friendliness and the clarity of the information it provided.
7	Notably, the application was independently installed by the patient in 91% of cases, with the
8	caregiver or the patient's doctor handling installation in the remaining instances. An analysis of
9	questionnaire responses, pertaining to AF knowledge furnished to patients at the time of
10	enrollment and post-hospital discharge, is presented in Figure 3. It was evident that patients had
11	incomplete initial knowledge about the disease and its treatment. However, after completing the
12	pathway and utilizing the informational resources available within the application, their knowledge
13	exhibited noticeable improvement, particularly concerning the recognition of symptoms and
14	anticoagulation therapy-related complications.

15 **DISCUSSION** 

We have described the implementation of a solution that combines a customized treatment 16 17 pathway with a patient mobile application, aimed at optimizing the management of patients 18 referred to our center for AF catheter ablation. The solution has been employed by the patients, 19 effectively guiding them along their care pathway and enhancing their understanding of the disease 20 and available therapies. The adoption of the system was widespread, particularly for pre-procedure 21 tasks. Adherence was commendable, and patients reported a positive user experience, even though 22 most used the system independently, without assistance from caregivers. These patients were not 23 predominantly elderly and may have been in better overall health than those with other conditions

1	for which similar aids have been proposed in the literature. It's worth mentioning that for other
2	chronic diseases, such as diabetes and heart failure, disease management programs have shown not
3	only significant improvements in patient knowledge, but also a positive impact on readmission and
4	mortality (7-12). The implementation of guideline-recommended management to individual AF
5	patients aims to enhance patient outcomes and reduce healthcare costs (13-15). Integrated AF
6	management has the potential to promote adherence to these guidelines, that is modest worldwide
7	(16-21). Various educational interventions (22-31), based on guideline-provided recommendations
8	and tailored to address specific knowledge gaps among AF patients, can facilitate the
9	implementation of guideline-based AF management to improve patient outcomes. Clinical
10	decision support systems, intelligent tools that digitize and provide evidence-based guidelines,
11	clinical pathways, and algorithms for personalized, timely, and evidence-based treatment, have
12	been used to enhance patient education, improve communication between patients and healthcare
13	professionals, and encourage active patient involvement (22, 32-35). The mobile AF (mAF) App
14	Trial (22) incorporated clinical decision-support tools, educational materials, and patient
15	involvement strategies with self-care protocols and follow-up. Results showed significant
16	improvements in knowledge, drug adherence, quality of life, and anticoagulation satisfaction.
17	Similarly, the pilot study on Mobile Applications for Seniors to enhance Safe anticoagulation
18	therapy (MASS) (34) demonstrated improved knowledge of oral anticoagulation therapy among
19	older adults. The Characterizing Atrial fibrillation by Translating its Causes into Health Modifiers
20	in the Elderly (CATCH ME) Consortium (33) developed mobile applications to engage patients,
21	optimize therapy, and enhance outcomes in AF, illustrating the value of integrating digital
22	technology into clinical practice. However, studies on the effectiveness of integrated AF
23	management have yielded mixed results (36-38), and further research is needed to identify cost-

1 effective intervention types that could more effectively enhance patient clinical outcomes,

2 medication adherence, and quality of life.

3 In our experience, we observed that patients generally adhered well to the deadlines for various 4 tasks, which is a positive outcome and certainly facilitates patient management throughout their treatment journey. Moreover, healthcare providers agreed that the system can offer an advantage in 5 improving the connection with patients and streamlining patient flow. However, the system was 6 not perceived as particularly advantageous for data collection and reducing follow-up time, 7 8 possibly because some tasks still required in-person attention. The process might be further improved, or the benefits could become more tangible with longer post-procedure follow-up to 9 evaluate arrhythmia recurrences and maintain a stronger patient connection. Post-procedure 10 compliance was not absolute within our population, and this could be improved by providing more 11 reminders to patients or by being more selective in patient enrollment in the care pathway. 12 13 Nevertheless, according to healthcare providers, the system offered the necessary functionalities to 14 facilitate its integration into clinical routine. In our project, we prioritized patient education in terms of information and instruction, as these 15 components are critical in the management of AF. Many studies have primarily focused on 16 17 knowledge related to anticoagulation therapy in AF patients or associated cardiovascular risks (39-18 45). Overall, patients' knowledge in these areas is lacking, with a low proportion of patients being 19 aware of their cardiac condition and the reasons for initiating anticoagulation therapy (39,40). 20 Understanding the nature and consequences of AF and appropriate therapy is essential for AF self-21 management (46,47). A previous study demonstrated the need for specific education programs and 22 their contribution to cardiovascular morbidity and mortality in AF patients (44). AF catheter 23 ablation is a complex procedure that may be associated with a range of specific post-procedural

complications. Although mostly rare, potentially serious complications may initially present with 1 2 non-specific symptoms and signs. International recommendations emphasize the importance of 3 fully informing patients about the clinical signs and symptoms of ablation-related complications 4 that may occur after hospital discharge and the significance of assessing procedural success and correlating symptom status with rhythm (1). Moreover, although clinical practice regarding 5 6 antiarrhythmic medication and anticoagulation therapy after ablation varies, there is a need for careful patient follow-up, adherence to indicated treatments, and monitoring of stroke risk factors 7 and rhythm status. In these aspects, the system proved to be effective. We confirmed that, although 8 our patients already had a diagnosis of AF and were referred for an ablative procedure (many with 9 a relatively long history of the disease and some in persistent AF), they did not possess sufficient 10 knowledge of the disease and treatments. Primarily, the system improved patients' knowledge of 11 symptoms and treatments through informational materials that patients could access 12 13 independently. Furthermore, the system is entirely customizable, offering the potential for further 14 improvements based on specific needs. 15 Limitations Our findings should be considered in light of potential limitations. This project was conducted at a 16 17 single center within a relatively short time frame in a non-randomized fashion. In addition, to test

the knowledge of patients with AF we decided to use a subset of questions from a validated
questionnaire (48) to make data collection through the mobile application less burdensome for the
patients.

21 *Future perspectives* 

22 To establish the system's effectiveness more conclusively, further research involving larger

23 populations and the assessment of well-defined, clinically relevant endpoints (e.g. clinical events,

1	arrhythmia recurrences), as well as validated and psychometrically tested instruments (e.g. quality
2	of life, knowledge questionnaire) is necessary and currently being planned. In addition, evidence is
3	necessary regarding efficiency for clinicians and support staff (e.g. total workload, number of
4	patient contacts, reduction in errors, appointment cancellations or scheduling adjustments).
5	Conclusions

- 6 In conclusion, our findings showed the successful implementation of a comprehensive solution
- 7 integrating a tailored treatment pathway and a patient mobile application for optimizing the
- 8 management of individuals referred to our center for AF catheter ablation. The adopted solution
- 9 demonstrated widespread use among patients, effectively guiding them through their care journey,
- 10 improving their understanding of the disease and available treatments.
- 11

### 12 ACKNOWLEDGEMENTS

The authors would like to acknowledge the highly professional help provided during the study by
Flavia Cortrie and Gema Roman Lopez (Boston Scientific Inc.,) and the work of Fionnuala Duffy
for her excellent project management of the Electrophysiology Research Group (Cardiovascular
Research Institute, the Royal College of Physicians in Ireland and the Mater Private Hospital,
Dublin).

18

# 19 **REFERENCES**

Hindricks G, Pótpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G,
 Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane
 DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC,
 Van Putte BP, Watkins CL; ESC Scientific Document Group. 2020 ESC Guidelines for the
 diagnosis and management of atrial fibrillation developed in collaboration with the European
 Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and

1		management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with
2		the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur
3		Heart J. 2021;42:373-498.
4	2.	Lane DA, Aguinaga L, Blomström-Lundqvist C, Boriani G, Dan GA, Hills MT, Hylek EM,
5		LaHaye SA, Lip GY, Lobban T, Mandrola J, McCabe PJ, Pedersen SS, Pisters R, Stewart S,
6		Wood K, Potpara TS, Gorenek B, Conti JB, Keegan R, Power S, Hendriks J, Ritter P, Calkins
7		H, Violi F, Hurwitz J. Cardiac tachyarrhythmias and patient values and preferences for their
8		management: the European Heart Rhythm Association (EHRA) consensus document endorsed
9		by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and
10		Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
11		Europace. 2015;17:1747-69.
12	3.	Desteghe L, Engelhard L, Raymaekers Z, Kluts K, Vijgen J, Dilling-Boer D, Koopman P,
13		Schurmans J, Dendale P, Heidbuchel H. Knowledge gaps in patients with atrial fibrillation
14		revealed by a new validated knowledge questionnaire. Int J Cardiol. 2016;223:906-914.
15	4.	Frankel DS, Parker SE, Rosenfeld LE, Gorelick PB. HRS/NSA 2014 Survey of Atrial
16		Fibrillation and Stroke: Gaps in Knowledge and Perspective, Opportunities for Improvement. J
17		Stroke Cerebrovasc Dis. 2015;24:1691-700.
18	5.	Lane DA, Ponsford J, Shelley A, Sirpal A, Lip GY. Patient knowledge and perceptions of atrial
19		fibrillation and anticoagulant therapy: effects of an educational intervention programme. The
20	7	West Birmingham Atrial Fibrillation Project. Int J Cardiol. 2006;110:354-8.
21	6.	McCabe PJ, Schad S, Hampton A, Holland DE. Knowledge and self-management behaviors of
22		patients with recently detected atrial fibrillation. Heart Lung. 2008;37:79-90.

1	7.	Bruce DG, Davis WA, Cull CA, Davis TM. Diabetes education and knowledge in patients with
2		type 2 diabetes from the community: the Fremantle Diabetes Study. J Diabetes Complications.
3		2003;17:82-9.
4	8.	Mehuys E, Van Bortel L, De Bolle L, Van Tongelen I, Annemans L, Remon JP, Giri M.
5		Effectiveness of a community pharmacist intervention in diabetes care: a randomized
6		controlled trial. J Clin Pharm Ther. 2011;36:602-13.
7	9.	Boyde M, Turner C, Thompson DR, Stewart S. Educational interventions for patients with
8		heart failure: a systematic review of randomized controlled trials. J Cardiovasc Nurs.
9		2011;26:E27-35.
10	10	. Gonseth J, Guallar-Castillón P, Banegas JR, Rodríguez-Artalejo F. The effectiveness of
11		disease management programmes in reducing hospital re-admission in older patients with heart
12		failure: a systematic review and meta-analysis of published reports. Eur Heart J. 2004;25:1570-
13		95.
14	11	. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the
15		management of heart failure patients at high risk for admission: a systematic review of
16		randomized trials. J Am Coll Cardiol. 2004;44:810-9.
17	12	. Davidson PM, Cockburn J, Newton PJ, Webster JK, Betihavas V, Howes L, Owensby DO.
18		Can a heart failure-specific cardiac rehabilitation program decrease hospitalizations and
19		improve outcomes in high-risk patients? Eur J Cardiovasc Prev Rehabil. 2010;17:393-402.
20	13	Nieuwlaat R, Olsson SB, Lip GY, Camm AJ, Breithardt G, Capucci A, Meeder JG, Prins MH,
21		Lévy S, Crijns HJ; Euro Heart Survey Investigators. Guideline-adherent antithrombotic
22		treatment is associated with improved outcomes compared with undertreatment in high-risk

1	patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J.
2	2007;153:1006-12.
3	14. Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA, Kalarus Z, Crijns
4	HJ, Oliveira MM, Tavazzi L, Maggioni AP, Boriani G. Improved outcomes with European
5	Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with
6	atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace. 2015;17:1777-
7	86.
8	15. Proietti M, Nobili A, Raparelli V, Napoleone L, Mannucci PM, Lip GY; REPOSI
9	investigators. Adherence to antithrombotic therapy guidelines improves mortality among
10	elderly patients with atrial fibrillation: insights from the REPOSI study. Clin Res Cardiol.
11	2016;105:912-920.
12	16. Schnabel RB, Pecen L, Ojeda FM, Lucerna M, Rzayeva N, Blankenberg S, Darius H, Kotecha
13	D, Caterina R, Kirchhof P. Gender differences in clinical presentation and 1-year outcomes in
14	atrial fibrillation. Heart. 2017;103:1024-1030.
15	17. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, Schmitt J,
16	Zamorano JL. Management of atrial fibrillation in seven European countries after the
17	publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the
18	PREvention oF thromboemolic eventsEuropean Registry in Atrial Fibrillation (PREFER in
19	AF). Europace. 2014;16:6-14.
20	18. Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, Darabantiu D,
21	Crijns HJ, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP, Boriani G. Prognosis and treatment
22	of atrial fibrillation patients by European cardiologists: one year follow-up of the

2 (EORP-AF Pilot registry). Eur Heart J. 2014;35:3365-76.

3	19. Jortveit J, Pripp AH, Langørgen J, Halvorsen S. Poor adherence to guideline recommendations
4	among patients with atrial fibrillation and acute myocardial infarction. Eur J Prev Cardiol.
5	2019;26:1373-1382.
6	20. Potpara TS, Dan GA, Trendafilova E, Goda A, Kusljugic Z, Manola S, Music L, Musetescu R,
7	Badila E, Mitic G, Paparisto V, Dimitrova ES, Polovina MM, Petranov SL, Djergo H, Loncar
8	D, Bijedic A, Brusich S, Lip GY; BALKAN-AF Investigators. Stroke prevention in atrial
9	fibrillation and 'real world' adherence to guidelines in the Balkan Region: The BALKAN-AF
10	Survey. Sci Rep. 2016;6:20432.
11	21. Miyazawa K, Li YG, Rashed WA, Al Mahmeed W, Shehab A, Zubaid M, Lip GYH.
12	Secondary stroke prevention and guideline adherent antithrombotic treatment in patients with
13	atrial fibrillation: Insights from the Gulf Survey of atrial fibrillation events (Gulf SAFE). Int J
14	Cardiol. 2019;274:126-131.
15	22. Guo Y, Chen Y, Lane DA, Liu L, Wang Y, Lip GYH. Mobile Health Technology for Atrial
16	Fibrillation Management Integrating Decision Support, Education, and Patient Involvement:
17	mAF App Trial. Am J Med. 2017;130:1388-1396.e6.
18	23. Clarkesmith DE, Pattison HM, Khaing PH, Lane DA. Educational and behavioural
19	interventions for anticoagulant therapy in patients with atrial fibrillation. Cochrane Database
20	Syst Rev. 2017;4:CD008600.

- 24. Karlsson LO, Nilsson S, Bång M, Nilsson L, Charitakis E, Janzon M. A clinical decision
- support tool for improving adherence to guidelines on anticoagulant therapy in patients with

1	atrial fibrillation at risk of stroke: A cluster-randomized trial in a Swedish primary care setting
2	(the CDS-AF study). PLoS Med. 2018;15:e1002528.

- 3 25. Desteghe L, Germeys J, Vijgen J, Koopman P, Dilling-Boer D, Schurmans J, Delesie M,
- 4 Dendale P, Heidbuchel H. Effectiveness and usability of an online tailored education platform
- 5 for atrial fibrillation patients undergoing a direct current cardioversion or pulmonary vein
- 6 isolation. Int J Cardiol. 2018;272:123-129.
- 7 26. Márquez-Contreras E, Martell-Claros N, Márquez-Rivero S, Hermida-Campa E, Gracia-Diez
- 8 C, Sanchez-López E, Gil-Guillén V; Compliance and Inertia Working Group, Spanish Society
- 9 of Hypertension (SEH-LELHA). Strategies for improving dabigatran adherence for stroke
- prevention in patients with non-valvular atrial fibrillation: education and drug intake reminders
  (FACILITA study). Curr Med Res Opin. 2018;34:1301-1308.
- 12 27. Heidbuchel H, Dagres N, Antz M, Kuck KH, Lazure P, Murray S, Carrera C, Hindricks G,
- 13 Vahanian A. Major knowledge gaps and system barriers to guideline implementation among
- 14 European physicians treating patients with atrial fibrillation: a European Society of Cardiology
- 15 international educational needs assessment. Europace. 2018;20:1919-1928.
- 16 28. Piccini JP, Xu H, Cox M, Matsouaka RA, Fonarow GC, Butler J, Curtis AB, Desai N, Fang M,
- 17 McCabe PJ, Page Ii RL, Turakhia M, Russo AM, Knight BP, Sidhu M, Hurwitz JL,
- Ellenbogen KA, Lewis WR; Get With The Guidelines-AFIB Clinical Working Group and
  Hospitals. Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation
  Is Achievable. Circulation. 2019;139:1497-1506.
- 21 29. Richardson KM, Singh J, Muñoz D, Damp JB, Mendes LA. Improving Practice Guideline
   22 Adherence Through Peer Feedback: Impact of an Ambulatory Cardiology Curriculum. Teach
- 23 Learn Med. 2018;30:328-336.

1	30. Ferguson C, Hickman LD, Phillips J, Newton PJ, Inglis SC, Lam L, Bajorek BV. An mHealth
2	intervention to improve nurses' atrial fibrillation and anticoagulation knowledge and practice:
3	the EVICOAG study. Eur J Cardiovasc Nurs. 2019;18:7-15.
4	31. Siebenhofer A, Ulrich LR, Mergenthal K, Berghold A, Pregartner G, Kemperdick B, Schulz-
5	Rothe S, Rauck S, Harder S, Gerlach FM, Petersen JJ. Primary care management for patients
6	receiving long-term antithrombotic treatment: A cluster-randomized controlled trial. PLoS
7	One. 2019;14:e0209366.
8	32. Parimbelli E, Sacchi L, Budasu R, Napolitano C, Peleg M, Quaglini S. The Role of Nurses in
9	E-Health: The MobiGuide Project Experience. Stud Health Technol Inform. 2016;225:153-7.
10	33. Kotecha D, Chua WWL, Fabritz L, Hendriks J, Casadei B, Schotten U, Vardas P, Heidbuchel
11	H, Dean V, Kirchhof P; European Society of Cardiology (ESC) Atrial Fibrillation Guidelines
12	Taskforce, the CATCH ME consortium and the European Heart Rhythm Association (EHRA).
13	European Society of Cardiology smartphone and tablet applications for patients with atrial
14	fibrillation and their health care providers. Europace. 2018;20:225-233.
15	34. Lee JA, Evangelista LS, Moore AA, Juth V, Guo Y, Gago-Masague S, Lem CG, Nguyen M,
16	Khatibi P, Baje M, Amin AN. Feasibility Study of a Mobile Health Intervention for Older
17	Adults on Oral Anticoagulation Therapy. Gerontol Geriatr Med. 2016;2:2333721416672970.
18	35. Stephan LS, Dytz Almeida E, Guimaraes RB, Ley AG, Mathias RG, Assis MV, Leiria TL.
19	Processes and Recommendations for Creating mHealth Apps for Low-Income Populations.
20	JMIR Mhealth Uhealth. 2017;5:e41.
21	36. Vinereanu D, Lopes RD, Mulder H, Gersh BJ, Hanna M, de Barros E Silva PGM, Atar D,
22	Wallentin L, Granger CB, Alexander JH; ARISTOTLE Investigators. Echocardiographic Risk
22	Wallentin L, Granger CB, Alexander JH; ARISTOTLE Investigators. Echocardiographic Ri

1	Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With
2	Apixaban or Warfarin. Stroke. 2017;48:3266-3273.
3	37. Vinereanu D, Lopes RD, Bahit MC, Xavier D, Jiang J, Al-Khalidi HR, He W, Xian Y,
4	Ciobanu AO, Kamath DY, Fox KA, Rao MP, Pokorney SD, Berwanger O, Tajer C, de Barros
5	E Silva PGM, Roettig ML, Huo Y, Granger CB; IMPACT-AF investigators. A multifaceted
6	intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF):
7	an international, cluster-randomised trial. Lancet. 2017;390:1737-1746.
8	38. Carter L, Gardner M, Magee K, Fearon A, Morgulis I, Doucette S, Sapp JL, Gray C,
9	Abdelwahab A, Parkash R. An Integrated Management Approach to Atrial Fibrillation. J Am
10	Heart Assoc. 2016;5:e002950.
11	39. Lip GY, Kamath S, Jafri M, Mohammed A, Bareford D. Ethnic differences in patient
12	perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial
13	Fibrillation Project. Stroke. 2002;33:238-42.
14	40. Nadar S, Begum N, Kaur B, Sandhu S, Lip GY. Patients' understanding of anticoagulant
15	therapy in a multiethnic population. J R Soc Med. 2003;96:175-9.
16	41. Smith DE, Xuereb CB, Pattison HM, Lip GY, Lane DA. TRial of an Educational intervention
17	on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and
18	outcome of Treatment with warfarin (TREAT). BMC Cardiovasc Disord. 2010;10:21.
19	42. Smith MB, Christensen N, Wang S, Strohecker J, Day JD, Weiss JP, Crandall BG, Osborn JS,
20	Anderson JL, Horne BD, Muhlestein JB, Lappe DL, Moss H, Oliver J, Viau K, Bunch TJ.
21	Warfarin knowledge in patients with atrial fibrillation: implications for safety, efficacy, and
22	education strategies. Cardiology. 2010;116:61-9.

1	43. Rewiuk K, Bednarz S, Faryan P, Grodzicki T. Knowledge of antithrombotic prophylaxis
2	among patients with atrial fibrillation. Cardiol J. 2007;14:44-9.
3	44. Aliot E, Breithardt G, Brugada J, Camm J, Lip GY, Vardas PE, Wagner M; Atrial Fibrillation
4	AWareness And Risk Education group; Atrial Fibrillation Association; European Heart
5	Rhythm Association; Stroke Alliance for Europe; World Heart Federation. An international
6	survey of physician and patient understanding, perception, and attitudes to atrial fibrillation
7	and its contribution to cardiovascular disease morbidity and mortality. Europace. 2010;12:626-
8	33.
9	45. Sloma A, Backlund LG, Strender LE, Skånér Y. Knowledge of stroke risk factors among
10	primary care patients with previous stroke or TIA: a questionnaire study. BMC Fam Pract.
11	2010;11:47.
12	46. Lane DA, Ponsford J, Shelley A, Sirpal A, Lip GY. Patient knowledge and perceptions of atrial
13	fibrillation and anticoagulant therapy: effects of an educational intervention programme. The
14	West Birmingham Atrial Fibrillation Project. Int J Cardiol. 2006;110:354-8.
15	47. Barlow J, Wright C, Sheasby J, Turner A, Hainsworth J. Self-management approaches for
16	people with chronic conditions: a review. Patient Educ Couns. 2002;48:177-87.
17	48. Desteghe L, Engelhard L, Raymaekers Z, Kluts K, Vijgen J, Dilling-Boer D, Koopman P,
18	Schurmans J, Dendale P, Heidbuchel H. Knowledge gaps in patients with atrial fibrillation
19	revealed by a new validated knowledge questionnaire. Int J Cardiol. 2016;223:906-914.
20 21	
22	Y
23 24	
25	
26 27	

# **1 FIGURE LEGENDS**

- 2 **Figure 1.** Description of the customized treatment path based on the application.
- 3 Figure 2. Patient compliance with the steps required by the treatment path and execution timings.
- 4 Figure 3. Survey questions on patient atrial fibrillation knowledge (PRE-Admission: 60
- 5 respondents, POST-Discharge: 43 respondents).
- 6
- 7 **Table 1.** Demographics and baseline clinical parameters.

Parameter	N = 63
Male Gender, n (%)	43 (68%)
Age, years	63 ± 12
History of Atrial Fibrillation, n (%)	
Paroxysmal	37 (59%)
Persistent	26 (41%)
Coronary artery disease, n (%)	8 (13%)
Heart Failure, n (%)	1 (2%)
Hypertension, n (%)	30 (48%)
Diabetes mellitus, n (%)	5 (8%)
COPD, n (%)	0 (0%)
Chronic kidney disease, n (%)	3 (5%)
Peripheral arterial disease, n (%)	3 (5%)
LV ejection fraction <50%, n (%)	3 (5%)
Prior stroke, n (%)	2 (3%)
CHA2DS2-VASc score (score ≥2)	32 (51%)
Ablation procedure, n (%)	59 (94%)
Point-by-point radiofrequency, n (%)	12 (20%)
Pulsed field ablation, n (%)	47 (80%)

	Strongly disagree	Disagree	Neutral	Agree	Strongly agree
Factors that allowed the successful im	<u> </u>	n of the Ab	lation Solu	ition	agree
Support for carepath customization	0 (0%)	0 (0%)	1 (14%)	2 (29%)	4 (57%)
Project management for deployment	0 (0%)	0 (0%)	1 (11%)	2 (27%) 4 (57%)	2 (29%)
Materials to support patient education	0 (0%)	0 (0%)	0 (0%)	3 (43%)	4 (57%)
and adoption	0 (070)	0 (070)	0 (070)	5 (1570)	
The Ablation Solution allowed to:					
Improve connectivity with patients	1 (14%)	0 (0%)	2 (29%)	0 (0%)	4 (57%)
Reduce the time needed to follow up	0 (0%)	4 (57%)	3 (43%)	0 (0%)	0 (0%)
with patients			. ,		
Collect patient information	0 (0%)	3 (43%)	3 (43%)	0 (0%)	1 (14%)
Streamline patient flow	0 (0%)	0 (0%)	1 (14%)	4 (57%)	2 (29%)
Reinforce the brand image of the	0 (0%)	0 (0%)	2 (29%)	4 (57%)	1 (14%)
hospital					
The Ablation Solution:					
Was easy to use	0 (0%)	0 (0%)	2 (29%)	2 (29%)	3 (43%)
Offered the required functionalities to	0 (0%)	0 (0%)	0 (0%)	3 (43%)	4 (57%)
facilitate its use in clinical routine					
I would recommend it to another	0 (0%)	0 (0%)	0 (0%)	2 (29%)	5 (71%)
hospital				. ,	. /
· · · · · · · · · · · · · · · · · · ·					

Table 2. Survey questions on operator experience with the Ablation Solution (7 respondents). 


- **Table 3.** Survey questions on patient experience (44 respondents).

Strongly	Disagree	Neutral	Agree	Strongly agree
uisagi ee				agree
0 (0)	0 (0)	1 (2)	31 (71)	12 (27)
1 (2)	0 (0)	5 (11)	24 (55)	14 (32)
0 (0)	0 (0)	3 (7)	28 (64)	13 (29)
0 (0)	0 (0)	0 (0)	32 (73)	12 (27)
40 (91)				
3 (7)				
1 (2)				
	disagree 0 (0) 1 (2) 0 (0) 0 (0) 40 (91) 3 (7)	disagree           0 (0)         0 (0)           1 (2)         0 (0)           0 (0)         0 (0)           0 (0)         0 (0)           0 (0)         0 (0)           40 (91)         3 (7)	disagree         0 (0)       0 (0)       1 (2)         1 (2)       0 (0)       5 (11)         0 (0)       0 (0)       3 (7)         0 (0)       0 (0)       0 (0)         40 (91)       3 (7)	disagree       0       0       0       0       1       2       31       (71)         1       (2)       0       (0)       5       (11)       24       (55)         0       (0)       0       (0)       3       (7)       28       (64)         0       (0)       0       (0)       0       (0)       32       (73)         40       (91)       3       (7)       3       (7)       (7)       (7)

2 Figure 1.

1

# Ablation Carepath



Materials legend:

8 Filled-in by clinical team

Filled-in by/info for patients Scheduled appointment





Figure 3. 



\*: Proportion of patients who answered the single-choice question correctly #: Patient-based average of correct answers for multiple-choice question \$: p<0.05 versus PRE, pairwise comparison



Downloaded from https://academic.oup.com/ehjdh/advance-article/doi/10.1093/ehjdh/ztae041/7680224 by Boston Scientific Corp Arden Hills user on 27 May 2024

# Key question

Catheter ablation of AF is safe and effective, however:

It is advisable to discuss its efficacy and potential complications with patients before proposing the procedure

Patients should be educated on the management of stroke risk and the use of oral anticoagulant therapy, both before and after the ablation procedure

1

2 3

# The ADVANTICS<sup>™</sup> ablation solution

An advisory program to support the digitization of the care path The optimized pathway was

established: A clear sequence of events

within the process Designated responsibility for data entry (clinical team

or patients)

The timing of action execution

A customized digital care coordination platform

Patient notifications

Patient educational material (regarding disease and treatment)

Engagement material (content of questionnaires)

Graphical Abstract 178x112 mm (DPI)

# Take-home messages

The patient-centered, integrated care strategy the care of AF catheter ablation candidates and bridge specific knowledge gaps among patients

- ✓ Widespread adoption
- Strong patient adherence to the pathway
- High operator and patient satisfaction
- Improved patient understanding of the disease and available treatments



Physician dashboard

Coordinator dashboard

